Advancing new therapies for Parkinson’s disease requires carefully designed clinical trials that address the unique scientific, regulatory and operational challenges of neurologic drug development. As symptomatic and disease-modifying treatments continue to evolve, sponsors must adapt and navigate trial designs, endpoint selection and development strategies to move programs forward efficiently.
In this webinar, experts from Dr. Vince Clinical Research (DVCR), joined by moderator Polly Dawkins, Executive Director of the Davis Phinney Foundation, will discuss the latest developments shaping Parkinson’s disease clinical research. The session will examine key considerations across symptomatic and disease-modifying study designs, with a focus on patient-centered research and successful trial execution.
Drawing on DVCR’s extensive experience conducting CNS clinical trials across psychiatric and neurologic indications, speakers will share real-world insights and case studies illustrating best practices for designing and managing successful Parkinson’s disease studies.
Key Takeaways:
- Key considerations for designing and optimizing Parkinson's disease clinical trials
- Emerging trends and recent developments in Parkinson's disease research
- Scientific and operational challenges associated with symptomatic and disease-modifying study designs
- Selection of outcome measures appropriate for patients with early- aand mid-stage Parkinson's disease
- How DVCR's full-service clinical development capabilities—from protocol development through clinical study report (CSR) publishing—support successful CNS drug development programs
Whether you are planning a First-in-Human study or preparing for NDA submission, this webinar will provide practical insights to help biopharma sponsors navigate the today’s complex Parkinson’s disease clinical trial landscape with greater confidence and efficiency.
